Convention on Psychotropic Substances

The Convention on Psychotropic Substances is a 1971 United Nations treaty that created an international scheduling framework for psychoactive substances — including stimulants, hallucinogens, sedatives, and tranquilizers — that were not covered by the earlier 1961 Single Convention on Narcotic Drugs. It was adopted in Vienna and entered into force in 1976.

The treaty divides controlled substances into four schedules and obligates signatory states to enact domestic laws giving effect to those schedules. Because implementation is left to individual countries, a substance's international schedule does not by itself determine its legal status anywhere.

What it means in practice

Schedule I carries the most restrictive provisions: substances placed there are described in the treaty as having serious abuse potential and very limited or no accepted therapeutic use, and signatories are expected to prohibit their manufacture, trade, and possession except under license for scientific or medical purposes. Schedules II through IV permit progressively broader medical use with appropriate licensing.

Substances are added to, transferred between, or removed from schedules through a process involving a World Health Organization expert review and a vote by the Commission on Narcotic Drugs.

The Schedule I language refers to substances having no currently accepted medical use. This is a statutory test that triggers the highest tier of controls — not a scientific finding about therapeutic potential.

How jurisdictions vary

Because the Convention requires domestic implementation rather than direct enforcement, signatory states write their own statutes, which differ in what they prohibit, what research exceptions they allow, and what penalties apply.

The United States implemented the Convention through the Controlled Substances Act, mapping substances onto a separate five-schedule system whose tier numbers do not correspond to the international ones. Many European countries implement the Convention's obligations through national medicines or misuse-of-drugs legislation with their own distinct schedule structures.

Some jurisdictions have moved ahead of the international framework. Portugal decriminalized personal possession across all schedules in 2001 while retaining supply offences. The Netherlands maintains a formal tolerance policy for certain controlled substances despite their international classification. Several countries have issued compassionate-use authorizations or begun domestic rescheduling proceedings for substances that remain in Schedule I internationally.

What is contested

The most persistent tension involves substances in Schedule I described as having no accepted medical use. Psilocybin and MDMA carry Schedule I equivalents in most domestic implementations, a status that historically restricted clinical research access.

Subsequent regulatory-track clinical trials in the United States and Europe have documented therapeutic signals for both substances in specific psychiatric conditions. Several jurisdictions have responded with compassionate-use exemptions or rescheduling reviews, while the international classification has not changed. The treaty classification and the current published clinical record point in different directions.

Scope and currency

This entry describes the Convention on Psychotropic Substances as an international instrument, as of August 2026. It is not legal advice and does not describe the law in any particular country.

What the Convention requires and what any jurisdiction actually permits for possession, supply, or research are determined by domestic legislation, which varies substantially. For the legal status of a specific substance, see the legal status section on that substance's page — each entry carries its own jurisdiction, date, and source.